Mallinkrodt was being investigated in connection with big price increases for its drug Achthar Gel. » Read More
Merck Group CEO Stefan Oschmann discusses his outlook for 2017 and how big data is transforming the pharmaceuticals industry. » Read More
Merck Group CEO Stefan Oschmann speaks about how his world has changed after Donald Trump's election. » Read More
CNBC's Meg Tirrell reports the latest surrounding California's Proposition 61. The "Fast Money" traders weigh in.
The pharmacy operator filed a sealed complaint against Theranos in Delaware.
Valeant shares were down 22 percent on Tuesday, but Wells Fargo's David Maris says the company still has some time to right the ship.
David Maris, Wells Fargo Securities managing director and equity research analyst, discusses Valeant Pharmaceutical's quarterly results.
Senior Research Analyst David Amsellem says, "We had never viewed the previous ranges as credible."
Shares of the No. 2 U.S. drugstore chain by store count were down about 16 percent at $69.22 in premarket trading.
Valeant Pharmaceuticals reported an 11 percent fall in quarterly revenue due to faltering sales, and cut its full-year profit and revenue forecasts.
Christophe Weber, CEO of Takeda Pharmaceuticals, talks about drug pricing and Takeda's acquisition plans in the gastroenterology, oncology and CNS spaces.
More than $125 million has been spent over an initiative to bar state agencies from paying more for drugs than the Veterans Affairs Department pays.
Greg Zuckerman, WSJ reporter, discusses how the plunge in biotech contributed to a $26 billion loss in hedge fund Paulson & Co.
Pharmaceutical stocks have been under pressure, but certain companies are doing things right, former Medtronic CEO Bill George says.
A report said Endo has held talks to sell Paladin Labs, its specialty pharmaceutical subsidiary.
Larry McDonald, ACG Analytics, and Erin Gibbs, S&P Global, discuss the moves in the IBB biotech ETF with Brian Sullivan.
Drugmaker Mylan may have overcharged hospitals that serve significant numbers of poor people for lifesaving anti-allergy devices.
Strategas Research Partners predicts Donald Trump has a 42 percent chance to win the election, based on stock market moves.
We're the big innovator, say Jonathan Ayers, IDEXX Laboratories CEO, talking about advances in diagnostics, software and services in veterinary medicine. Also Ayer weighs in on potential growth trends among millennial pet owners.
Get the best of CNBC in your inbox